Melanotan II for Health & Longevity

Evidence Review created on 04/20/2026 using AI4L / Opus 4.7

Also known as: MT-II, MT-2, Melanotan 2, Barbie Drug

Motivation

Melanotan II is a synthetic peptide originally engineered in the 1980s as a highly potent variant of one of the body’s own pigment-signaling hormones. It was designed to induce protective skin pigmentation without sun exposure, but its activity at several related biological switches also produces effects on sexual arousal, appetite, and the cardiovascular system.

Although pharmaceutical development was halted in favor of more selective derivatives, Melanotan II remains widely distributed through unregulated online vendors and peptide forums. Users typically pursue cosmetic tanning, enhanced libido, or appetite suppression, and several national medicine regulators have issued warnings after reports of skin lesions, cardiovascular events, and prolonged painful erections associated with its use.

This review examines the available evidence on Melanotan II’s mechanisms, expected benefits, documented risks, therapeutic protocol, sourcing concerns, and practical considerations as they relate to a health- and longevity-focused audience, and identifies the substantial gaps that remain in controlled human data.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Melanotan II

Dedicated entry describing MT-II as a synthetic cyclic heptapeptide analogue of alpha-MSH, covering its structural design, synthesis, pharmacology across the melanocortin receptors, and its reported effects on pigmentation, sexual function, and appetite.

Examine

No dedicated Examine.com article for Melanotan II was found. Examine.com focuses on dietary supplements and does not typically cover unregulated injectable peptides such as MT-II.

ConsumerLab

No dedicated ConsumerLab.com article for Melanotan II was found. ConsumerLab.com reviews commercially available dietary supplements and does not typically cover unregulated injectable peptides.

Systematic Reviews

No systematic reviews or meta-analyses for Melanotan II were found on PubMed as of 04/20/2026.

Mechanism of Action

MT-II is a synthetic cyclic heptapeptide that non-selectively activates the family of five melanocortin receptors (MC1R through MC5R), which are G protein-coupled receptors (GPCRs, cell-surface receptors that relay external signals into the cell through G proteins). Its biological effects emerge from simultaneous activity at several of these receptors:

Skin pigmentation via MC1R: MT-II binds MC1R on melanocytes (pigment-producing cells in the basal layer of the skin), raising intracellular cAMP (cyclic adenosine monophosphate, a key signaling molecule). Downstream activation of protein kinase A and the transcription factor MITF (microphthalmia-associated transcription factor, the master regulator of melanocyte biology) upregulates tyrosinase and other enzymes, shifting melanocyte output toward eumelanin (the brown-black photoprotective pigment) rather than pheomelanin (the red-yellow pigment associated with fair skin).
Central effects on sexual function via MC3R and MC4R: MT-II crosses the blood-brain barrier and activates MC4R (melanocortin-4 receptor, a hypothalamic receptor involved in appetite, energy balance, and sexual behavior) in the paraventricular nucleus, triggering oxytocin release and pro-erectile parasympathetic outflow. The resulting erections occur through a central mechanism that is distinct from peripheral vasodilators such as PDE5 inhibitors (phosphodiesterase type 5 inhibitors such as sildenafil that act on penile vascular smooth muscle).
Appetite suppression via MC3R and MC4R: MC4R activation in the hypothalamus suppresses orexigenic NPY/AgRP (neuropeptide Y / agouti-related peptide, appetite-stimulating signals) neurons and enhances anorexigenic POMC (pro-opiomelanocortin, the precursor cleaved into alpha-MSH and other peptides) signaling. In rodent models this produces sustained reductions in food intake and visceral adiposity.
Cardiovascular activation via MC4R: Central MC4R stimulation increases sympathetic nervous system outflow, which raises heart rate and blood pressure. This sympathoexcitatory response was a principal reason pharmaceutical development of MT-II was halted.
Anti-inflammatory signaling via MC1R and MC3R: Preclinical work indicates that melanocortin agonism can suppress NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a master regulator of inflammatory gene expression) signaling and reduce TNF-α, IL-6, and IL-1β, with mixed evidence for downstream cardiovascular protection. Some authors argue this is where melanocortin pharmacology holds the most durable therapeutic promise; others emphasize that MT-II’s cardiovascular activation may offset any vascular anti-inflammatory benefit.

Pharmacological properties: MT-II is a synthetic cyclic lactam-bridged heptapeptide, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. It is administered subcutaneously. Published human pharmacokinetic data are sparse; circulating half-life in the original Phase I work was short (on the order of hours), while its downstream pigmentation effects persist for weeks because they are sustained by long-lived melanin deposition in keratinocytes. MT-II is non-selective across MC1R–MC5R; it is not metabolized by CYP enzymes (it is a peptide cleared by peptidases) and does not follow hepatic CYP pharmacokinetics. Its active derivative bremelanotide (PT-141) is produced through loss of the C-terminal amide in vivo and in vitro.

Historical Context & Evolution

MT-II’s development is a frequently cited example of how a peptide designed for one indication revealed several unexpected pharmacological activities, which in turn drove the search for more selective derivatives:

1980s: Mac Hadley and Victor Hruby at the University of Arizona launched systematic structure-activity studies on alpha-MSH, aiming to create enzymatically stable, superpotent analogues that could induce protective tanning and thereby reduce skin cancer incidence.
1991: The cyclic lactam-bridged heptapeptide Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 was identified as a superpotent melanotropic peptide and designated Melanotan II. The substitution of norleucine for methionine, incorporation of D-phenylalanine, and cyclization via a lactam bridge together conferred protease resistance and constrained the bioactive conformation.
1996: Dorr et al. published the first Phase I clinical study of MT-II in three male volunteers, documenting skin tanning after only five low subcutaneous doses and unexpectedly observing spontaneous erections, a yawning-stretching complex, and nausea.
1998–2000: Wessells and colleagues published double-blind, placebo-controlled crossover studies of MT-II in men with psychogenic erectile dysfunction (ED, persistent difficulty achieving or maintaining an erection sufficient for sexual activity) and, later, men with organic ED, showing that a single subcutaneous dose induced clinically meaningful erections in the majority of subjects and raised self-reported sexual desire.
Early 2000s: Because MT-II’s non-selective receptor profile produced nausea, blood pressure elevations, and tachycardia that complicated cosmetic and sexual applications, pharmaceutical development was discontinued. Instead, its active metabolite bremelanotide (PT-141) was advanced as a more selective MC4R agonist.
2000s–2010s: MT-II became widely available through unregulated online vendors and spread through bodybuilding and aesthetic subcultures under the nickname “Barbie drug.” National regulators, including the US Food and Drug Administration (FDA), Australia’s Therapeutic Goods Administration (TGA, the national regulator for medicines and medical devices), and the UK Medicines and Healthcare products Regulatory Agency (MHRA, the UK regulator for medicines), issued consumer warnings.
2011 onward: Case reports and case series accumulated, describing melanoma, eruptive dysplastic nevi, melanonychia, priapism, rhabdomyolysis (severe muscle breakdown), and renal injury in MT-II users. Authors differ on causation: some argue concurrent sunbed exposure and background melanoma risk largely account for these reports, while others emphasize MT-II’s direct melanocyte-stimulating activity as a plausible contributor that cannot be excluded from the available evidence.
2019: Bremelanotide (Vyleesi), the MC4R-targeted derivative of MT-II, received FDA approval for hypoactive sexual desire disorder in premenopausal women, representing the only approved therapeutic outgrowth of the original MT-II program.
2020: Setmelanotide, a selective MC4R agonist distantly inspired by the same melanocortin work, received FDA approval for rare monogenic obesity syndromes caused by POMC, PCSK1 (proprotein convertase subtilisin/kexin type 1, an enzyme that processes prohormone precursors), or LEPR (leptin receptor, a protein on the cell surface that binds leptin and regulates energy balance) deficiency.
2025–2026: A Phase II clinical trial (NCT07437560) evaluating MT-II as an adjunct to narrowband UV-B phototherapy for repigmentation in stable nonsegmental vitiligo began recruitment, representing a renewed attempt to study MT-II under controlled medical supervision.

Expected Benefits

Medium 🟩 🟩

Skin Pigmentation (Tanning)

MT-II reliably induces skin darkening through stimulation of eumelanin production. The Phase I study by Dorr et al. (1996, three subjects) documented measurable pigmentation of the face, upper body, and buttocks after five low subcutaneous doses. Subsequent user surveys describe visible tanning within 5–10 doses at standard regimens. The evidence base is limited to small Phase I trials and uncontrolled user reports, and most real-world users also use sunbeds, which confounds attribution to MT-II alone.

Magnitude: Visually perceptible and reflectance-measurable pigmentation increase after 5–10 subcutaneous doses at 0.025 mg/kg, typically appearing within 1–2 weeks.

Erectile Function Enhancement

Two double-blind, placebo-controlled crossover studies support an erectogenic effect. Wessells et al. (1998) reported clinically apparent erections in 8 of 10 men with psychogenic ED, with mean duration of more than 80% tip rigidity of 38 minutes on MT-II versus 3 minutes on placebo. Wessells et al. (2000) replicated this in 20 men with psychogenic and organic ED, observing erections in 17 of 20 subjects and increased sexual desire after 68% of MT-II doses versus 19% of placebo. These effects are centrally mediated and distinct from peripheral PDE5 inhibitor pharmacology.

Magnitude: Clinically apparent erections in approximately 80–85% of men with ED; mean rigid duration of 38–41 minutes; increased sexual desire after roughly 68% of MT-II doses compared with 19% of placebo.

Low 🟩

Appetite Suppression

Decreased appetite is a consistent clinical and user-reported effect of MT-II, with a well-characterized mechanism through hypothalamic MC4R activation. Rodent studies show dose-dependent suppression of food intake and sustained reductions in body mass and visceral fat. In humans, however, the anorexigenic effect appears transient with repeated dosing, and no controlled trials have evaluated MT-II as a weight-management intervention; user reports are heterogeneous.

Magnitude: Not quantified in available studies.

Speculative 🟨

Photoprotection & Skin Cancer Risk Reduction

The original rationale for MT-II was to induce a protective eumelanin tan that would reduce UV-induced DNA damage and skin cancer incidence. Eumelanin is more photoprotective than pheomelanin, and the related approved compound afamelanotide (Melanotan I) has demonstrated photoprotective benefit in erythropoietic protoporphyria. However, no human studies have evaluated whether MT-II-induced tanning reduces skin cancer risk, and concerns that MC1R stimulation could promote melanocytic proliferation complicate this theoretical benefit. The basis for this entry is mechanistic reasoning and extrapolation from afamelanotide rather than direct evidence.

Anti-Inflammatory & Cardiometabolic Effects

Preclinical models indicate that melanocortin receptor agonism reduces NF-κB signaling and pro-inflammatory cytokine production and can attenuate atherosclerotic plaque inflammation. No controlled human studies have evaluated MT-II for anti-inflammatory or cardiometabolic endpoints. The basis for this entry is animal and cell-culture data only, and MT-II’s sympathoexcitatory cardiovascular profile may offset any vascular benefit.

Female Sexual Function

Early observations in women and the subsequent approval of the MT-II-derived compound bremelanotide for hypoactive sexual desire disorder suggest that melanocortin agonism can modulate female sexual arousal. No controlled trials have evaluated MT-II itself in women at defined doses, and the approved, more selective derivative carries a better-characterized risk profile. The basis for this entry is mechanistic and the downstream clinical success of bremelanotide rather than direct MT-II data.

Benefit-Modifying Factors

MC1R genotype: Loss-of-function MC1R variants (common in fair-skinned and red-haired individuals; e.g., R151C, R160W, D294H) reduce melanogenic signaling and may blunt the tanning response to MT-II, even while systemic effects mediated by MC3R and MC4R continue. No pharmacogenomic guidance exists.
Baseline melanin levels (Fitzpatrick skin type): Individuals with lighter skin (Fitzpatrick I–II, very fair to fair) tend to notice the cosmetic tanning effect more dramatically because their baseline pigmentation is lower, though they also carry the highest baseline melanoma risk.
Baseline sexual function status: Men with psychogenic rather than organic ED showed the largest proportional improvement in the early trials; individuals with predominantly vascular ED may respond less to a centrally mediated agent than to a PDE5 inhibitor.
Sex-based differences: The erectile function data are male-only. Female sexual arousal effects have been observed but not systematically studied at defined MT-II doses; the approved derivative bremelanotide is indicated for premenopausal women with hypoactive sexual desire disorder and provides a better-characterized signal for women.
Age-related considerations: All clinical trials enrolled young to middle-aged adults. Older adults within the target audience may experience a less favorable benefit profile because age-related cardiovascular changes can amplify the sympathetic side-effects that limit tolerated dose, and accumulating baseline melanocytic lesions raise the stakes of any new melanocyte stimulation.
Pre-existing cardiovascular or renal disease: Individuals with hypertension or reduced renal function often cannot tolerate doses high enough to produce consistent cosmetic effects, limiting achievable benefit.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea

Nausea is the most consistently reported adverse effect across clinical trials and user surveys. In the Phase I study by Dorr et al. (1996), mild nausea was reported at most dose levels. User surveys report incidences of roughly 40–60%. Nausea typically begins within 30–60 minutes of injection and resolves within 1–3 hours.

Magnitude: Incidence approximately 40–60% across user surveys; severe nausea in roughly 10–15% at standard doses; generally self-limiting within 1–3 hours.

Melanocytic Changes (New & Altered Moles)

Multiple case reports and the narrative review by Habbema et al. (2017) document new melanocytic nevi, darkening and morphological change of existing nevi, eruptive dysplastic (atypical) nevi, and melanonychia (dark pigmentation of the nail bed) in MT-II users. Burian and Jemec (2019) included MT-II among recognized triggers of eruptive melanocytic nevi. These changes are biologically consistent with MT-II’s direct stimulation of melanocyte proliferation and pigment production.

Magnitude: Multiple case reports documenting new nevi, morphologic change of existing nevi, and eruptive dysplastic nevi; population-level incidence is unknown due to absence of systematic surveillance.

Medium 🟥 🟥

Melanoma Risk ⚠️ Conflicted

Several published case reports describe melanomas diagnosed during or shortly after MT-II use, and the narrative review by Habbema et al. (2017) catalogues melanoma and melanoma-in-situ cases in users. A 2025 case report by Yassin Alsabbagh et al. described oral mucosal malignant melanoma in a 22-year-old woman who used MT-II nasal spray. Sivyer (2012) documented the emergence of multiple changing melanocytic lesions in a teenager with familial atypical multiple mole melanoma (FAMMM) syndrome who used MT-II together with a sunbed. Authors disagree on causation. Some reviews argue that concurrent sunbed use and preexisting melanoma risk factors (fair skin, family history) plausibly account for most reported cases; others emphasize that MT-II’s direct melanocyte-stimulating action is biologically consistent with accelerated melanomagenesis and that this contribution cannot be excluded from current evidence.

Magnitude: At least five published melanoma or melanoma-in-situ case reports temporally associated with MT-II use; causation not established; concurrent UV exposure is a confounder in most reported cases.

Cardiovascular Effects (Tachycardia & Blood Pressure Changes)

Central MC4R activation increases sympathetic outflow, raising heart rate and blood pressure. Nelson et al. (2012) described a user who developed tachycardia peaking at 146 bpm and blood pressure of 151/85 mmHg after a 6 mg dose (roughly six times the recommended dose). User reports describe heart-rate increases of 10–20 bpm at standard doses in 15–25% of users. These sympathoexcitatory effects were a primary driver of the decision to halt MT-II development.

Magnitude: Heart-rate increases of approximately 10–20 bpm at standard doses; tachycardia reported in roughly 15–25% of users; blood pressure elevations documented; severe cardiovascular toxicity has been reported with supratherapeutic dosing.

Facial Flushing

Transient facial flushing, attributed to vascular melanocortin receptor activation and resulting vasodilation, is reported in 30–50% of users. It generally occurs within 15–30 minutes of injection and resolves within 1–2 hours without clinical consequence.

Magnitude: Incidence approximately 30–50% in user surveys; transient and self-limiting.

Low 🟥

Rhabdomyolysis & Renal Injury

Nelson et al. (2012) reported a case of severe rhabdomyolysis (creatine phosphokinase peaking at 17,773 IU/L; conventional reference <200 IU/L) and acute renal dysfunction (creatinine 2.25 mg/dL) requiring intensive-care admission and three days of intravenous fluids and sodium bicarbonate after a 6 mg MT-II dose. Additional case-level reports describe renal infarction in MT-II users, with both possible prothrombotic pharmacological effects and direct tissue effects considered. These are severe but rare adverse events, most strongly associated with supratherapeutic dosing.

Magnitude: Case reports of creatine phosphokinase elevation to 17,773 IU/L and creatinine to 2.25 mg/dL requiring intensive-care admission; additional reports of renal infarction; risk appears dose-dependent and concentrated at supratherapeutic doses.

Priapism

Dreyer et al. (2019) reported acute low-flow priapism (prolonged, painful erection unrelieved by the usual means and considered a urological emergency because persistent ischemia can destroy erectile tissue) after subcutaneous MT-II, requiring emergency cavernosal aspiration, irrigation, and intracavernosal phenylephrine. The patient had not recovered baseline erectile function at four-week follow-up.

Magnitude: Case report of priapism requiring emergency urological intervention with persistent erectile dysfunction at four-week follow-up.

Somnolence, Fatigue & Yawning-Stretching Complex

Dorr et al. (1996) documented Grade II somnolence and fatigue at 0.03 mg/kg, and a characteristic yawning-stretching complex that co-occurs with the onset of pro-erectile effects has been reported across studies and user accounts. These effects are typically dose-related and resolve within hours.

Magnitude: Grade II somnolence at 0.03 mg/kg; yawning-stretching complex commonly reported at standard doses; self-limiting.

Speculative 🟨

Endocrine & Metabolic Disruption

MT-II’s non-selective activation of melanocortin receptors has the theoretical potential to perturb the hypothalamic-pituitary-adrenal axis (the body’s central stress-hormone axis). An isolated case report associated melanotan-type injections with hypercortisolism, hyperglycemia, and ketosis in a patient with type 1 diabetes. No controlled human data exist on the endocrine consequences of chronic MT-II use; the basis for this entry is mechanistic reasoning and isolated reports.

Infection Risk from Unregulated Injection Practices

The qualitative study by Gilhooley et al. (2021) documented needle sharing, non-sterile injection technique, and reconstitution with non-sterile water among MT-II users. These practices carry risks of bloodborne-virus transmission (HIV, hepatitis B, hepatitis C) and local injection-site infections. The risk stems from the unregulated administration context rather than the peptide itself, and no surveillance data quantify its magnitude.

Unknown Long-Term Effects

There are no long-term controlled safety data for MT-II. The cumulative consequences of repeated melanocortin receptor stimulation on melanocyte biology, endocrine function, cardiovascular health, and cancer risk remain uncharacterized. The basis for this entry is the absence, rather than presence, of data.

Risk-Modifying Factors

MC1R and CDKN2A genotype: Individuals with MC1R loss-of-function variants can have an impaired tanning response while still experiencing full systemic side effects. Carriers of CDKN2A (cyclin-dependent kinase inhibitor 2A, a tumor-suppressor gene whose germline mutations substantially raise melanoma risk) mutations or the FAMMM syndrome phenotype face disproportionately elevated melanoma risk from any melanocyte-stimulating intervention.
Baseline cardiovascular and renal biomarkers: Individuals with baseline blood pressure above 140/90 mmHg, resting heart rate above 90 bpm, or elevated serum creatinine may experience amplified cardiovascular or renal side effects.
Sex-based differences: Men face a specific risk of priapism and of prolonged spontaneous erections. Women-specific risk data with MT-II are essentially absent; the 2025 oral mucosal melanoma case report described a young woman using MT-II nasal spray.
Age-related considerations: Older adults within the target audience carry greater cardiovascular and renal vulnerability and more accumulated baseline melanocytic lesions, which collectively produce a less favorable risk profile. No clinical trial data are available for adults over 65.
Pre-existing health conditions: Personal or family history of melanoma or dysplastic nevi is the most important individual risk modifier. Cardiovascular disease, uncontrolled hypertension, chronic kidney disease, sickle cell disease (for priapism risk), and active or past eating disorders (because of appetite suppression) each materially raise the risk profile.
Concurrent sunbed or high UV exposure: Combining MT-II (which stimulates melanocyte proliferation) with ultraviolet radiation (which damages melanocyte DNA) is the most consistently identified high-risk pattern across the case-report literature.

Key Interactions & Contraindications

PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra, avanafil/Stendra): MT-II’s pro-erectile effects may be additive with PDE5 inhibitors, increasing the risk of priapism or prolonged erection. Severity: caution to avoid. Consequence: priapism requiring emergency intervention. Mitigation: avoid concurrent use; if any PDE5 inhibitor exposure has occurred within the preceding 24–36 hours, MT-II administration should be deferred.
Antihypertensive medications (ACE inhibitors such as lisinopril/Zestril, angiotensin II receptor blockers such as losartan/Cozaar, beta blockers such as metoprolol/Lopressor, calcium channel blockers such as amlodipine/Norvasc): MT-II’s sympathoexcitatory effects can blunt or create unpredictable hemodynamic responses with antihypertensive regimens. Severity: caution and monitor. Consequence: loss of blood-pressure control or unexpected blood-pressure swings. Mitigation: more frequent home blood-pressure monitoring in the first weeks of use.
Anticoagulants and antiplatelet agents (warfarin/Coumadin, apixaban/Eliquis, rivaroxaban/Xarelto, clopidogrel/Plavix, low-dose aspirin): Given reports of renal infarction in MT-II users, concurrent anticoagulation or antiplatelet therapy combines an uncharacterized thrombotic-risk profile with bleeding risk. Severity: caution. Consequence: unpredictable thrombotic or bleeding outcomes. Mitigation: no data to support safe concurrent use; avoid combination.
Insulin and other antidiabetic agents (insulins, metformin/Glucophage, GLP-1 receptor agonists such as semaglutide/Ozempic): Appetite suppression and possible endocrine perturbation can destabilize blood-glucose control. Severity: caution and monitor. Consequence: hypoglycemia or loss of glycemic control. Mitigation: more frequent glucose checks during initiation and dose changes.
Over-the-counter sympathomimetic decongestants (pseudoephedrine/Sudafed, phenylephrine/Sudafed PE) and caffeine: Additive sympathoexcitatory effects alongside MT-II’s MC4R-mediated cardiovascular activation. Severity: caution. Consequence: tachycardia, blood-pressure elevation. Mitigation: avoid concurrent use during MT-II dosing windows.
Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen/Advil and naproxen/Aleve): Compound renal stress given documented associations with renal injury and rhabdomyolysis. Severity: caution. Consequence: elevated risk of acute kidney injury. Mitigation: avoid routine use during MT-II courses.
Sedating OTC antihistamines (diphenhydramine/Benadryl, doxylamine/Unisom): May potentiate somnolence and the yawning-stretching complex. Severity: caution. Consequence: daytime sedation, impaired driving. Mitigation: separate administration times.
Supplements with cardiovascular or sympathomimetic activity (yohimbine, synephrine/bitter orange, high-dose caffeine, ephedra-containing products): Theoretically potentiate MT-II’s cardiovascular effects. Severity: caution. Consequence: palpitations, hypertensive episodes. Mitigation: avoid concurrent use.
Supplements with additive vasodilatory or pro-erectile effects (L-citrulline, L-arginine, high-dose beetroot/nitrate supplements): May theoretically potentiate pro-erectile effects and priapism risk. Severity: caution. Consequence: prolonged erection. Mitigation: avoid concurrent high-dose use around MT-II dosing.
Other interventions (sunbeds and high-intensity UV exposure, other injectable peptides of uncertain purity): Sunbed use combined with MT-II is the most consistent high-risk pattern in the case-report literature. Severity: avoid. Consequence: markedly elevated melanocytic and melanoma risk.

Populations who should avoid MT-II:

Individuals with a personal or family history of melanoma, dysplastic nevus syndrome, or FAMMM syndrome (absolute contraindication in most expert commentary).
Individuals with uncontrolled hypertension (resting BP ≥140/90 mmHg) or established cardiovascular disease, including recent myocardial infarction (<90 days), unstable angina, or New York Heart Association (NYHA) Class III–IV heart failure.
Individuals with moderate-to-severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m²) or prior rhabdomyolysis.
Men with conditions predisposing to priapism, including sickle cell disease, sickle cell trait, multiple myeloma, or prior priapism episodes.
Pregnant or breastfeeding individuals (no safety data).
Individuals with active or past eating disorders, given appetite-suppressing effects.
Children and adolescents (no safety or efficacy data).

Risk Mitigation Strategies

Prefer approved alternatives first: MT-II’s principal use cases all have approved, better-characterized alternatives. This mitigates the underlying risk that MT-II use is undertaken without an evidence-based substitute: bremelanotide (Vyleesi) is approved for hypoactive sexual desire disorder in premenopausal women; PDE5 inhibitors are approved for male erectile dysfunction; evidence-based UV-protection strategies (SPF 30+ broad-spectrum sunscreen, UPF-rated clothing, sun avoidance during peak hours) address skin cancer risk directly rather than through pharmacological pigmentation.
Obtain medical supervision if used: To mitigate the documented dermatologic, cardiovascular, and renal risks, any use should occur under a clinician experienced in off-label peptide therapy, with documented baseline workup and structured follow-up monitoring rather than self-guided dosing.
Conduct baseline and periodic full-body skin examination: To mitigate melanocytic change and melanoma risk, obtain a baseline full-body skin examination with dermoscopic imaging (mole mapping) by a dermatologist before starting, and repeat every 3–6 months during and after use. Report any new pigmented lesion, or change in size, shape, color, or border of an existing lesion, immediately.
Avoid concurrent UV exposure and sunbeds entirely: To mitigate the most consistent high-risk pattern in the case-report literature (melanocyte stimulation combined with UV-induced DNA damage), avoid sunbed use during and for at least 3 months after MT-II exposure, and follow standard sun-protection measures (broad-spectrum SPF 30+ daily, UPF clothing, avoidance of peak-UV hours) throughout.
Use the lowest effective dose: To mitigate dose-dependent nausea, cardiovascular, and rhabdomyolysis risks, begin at no more than 0.01 mg/kg subcutaneously, titrate upward by increments of 0.005 mg/kg no more frequently than every 3–5 days, and do not exceed the Phase I reference dose of 0.025 mg/kg/day. Avoid doses ≥0.04 mg/kg, which have been associated with severe adverse events.
Source only through a licensed compounding pharmacy: To mitigate contamination, mislabeling, and dosing-accuracy risks associated with online vendors, require a certificate of analysis showing identity and purity, and confirm the pharmacy operates under current Good Manufacturing Practice (cGMP, internationally recognized quality standards for pharmaceutical production) standards.
Use sterile single-use injection supplies: To mitigate bloodborne-infection and injection-site-infection risks documented in forum studies, use single-use 27–30-gauge insulin syringes, bacteriostatic water for reconstitution, 70% isopropyl alcohol skin antisepsis, and never share injection supplies.
Monitor cardiovascular parameters around dosing: To mitigate sympathoexcitatory risk, check blood pressure and heart rate before the first injection and 1–2 hours after; discontinue if resting heart rate exceeds 100 bpm, systolic blood pressure rises by more than 20 mmHg, or the user develops chest pain, palpitations, or severe headache.
Discontinue immediately at any sign of severe adverse event: To mitigate progression of severe events, stop MT-II and seek urgent medical evaluation for a persistent erection lasting more than 2 hours (priapism), severe muscle pain with dark urine (possible rhabdomyolysis), flank pain (possible renal infarction), or any rapidly changing pigmented skin lesion.

Therapeutic Protocol

MT-II is not approved for any indication, and no standardized therapeutic protocol has been endorsed by a regulatory authority. The following summarizes doses used in published clinical trials and practices described by clinicians who prescribe off-label peptides.

Standard clinical-trial regimen: The Phase I work by Dorr et al. (1996) used subcutaneous doses starting at 0.01 mg/kg and escalating in 0.005 mg/kg increments; the recommended Phase I dose was 0.025 mg/kg/day. The erectile dysfunction studies by Wessells and colleagues used 0.025 mg/kg subcutaneously. For a 75 kg individual, 0.025 mg/kg corresponds to approximately 1.875 mg per dose.
Competing approaches and who popularized them: The “tanning protocol” most commonly described in unregulated use (originating in European bodybuilding communities) employs a loading phase of daily low-dose injections (0.25–0.5 mg) for 1–3 weeks until desired pigmentation is reached, followed by weekly or twice-weekly maintenance doses. A more conservative clinician-guided approach, associated with off-label integrative peptide clinicians, instead uses a single non-daily Phase I–style dose (roughly 0.01–0.025 mg/kg every 2–3 days) with structured monitoring. A third approach, reflected in the active Phase II vitiligo trial (NCT07437560), administers MT-II as an adjunct to narrowband UV-B phototherapy under dermatology supervision. None of these approaches is a default; only the vitiligo trial approach is under formal medical oversight.
Route of administration: Subcutaneous injection is the only route used in controlled human studies. Nasal-spray formulations are sold through unregulated channels and have unknown bioavailability.
Best time of day: Clinical trials administered MT-II during daytime hours with post-dose observation. Because nausea, flushing, and somnolence begin within 30–60 minutes and peak within 1–2 hours, many clinicians who prescribe off-label suggest evening dosing so peak side effects occur at rest; this has not been formally studied.
Half-life: Published human pharmacokinetic parameters are sparse. Circulating half-life is short (on the order of a few hours), while pigmentation persists for weeks because it is sustained by melanin deposition in keratinocytes.
Single vs. split dosing: All controlled studies used a single subcutaneous dose per day. Splitting the daily dose has not been studied; because acute side effects (nausea, flushing, somnolence) are tied to each injection event, splitting the dose could multiply periods of side effects without an established efficacy benefit.
Genetic polymorphisms: Carriers of MC1R loss-of-function variants may require higher doses to achieve visible tanning, but this would also amplify systemic MC3R/MC4R effects; no pharmacogenomic dosing guidance exists.
Sex-based differences: Pro-erectile dosing is relevant only to men. Women-specific dosing has not been established; the approved derivative bremelanotide is dosed independently and is not interchangeable with MT-II.
Age-related considerations: No age-specific dosing adjustments exist. Older adults within the target audience should start at the lowest dose and titrate more slowly because of cardiovascular and renal vulnerability.
Baseline biomarker levels: Blood pressure, heart rate, renal function, and a comprehensive skin examination should be documented before any use; abnormal values warrant deferral.
Pre-existing conditions: Cardiovascular disease, renal impairment, melanoma history, and priapism-risk conditions should preclude use.

Discontinuation & Cycling

Lifelong vs. short-term: MT-II is not appropriate for lifelong use given the absence of long-term safety data and the biologically plausible concern about cumulative melanocyte stimulation. In unregulated practice it is typically used in short courses (2–4 weeks) to reach target pigmentation, followed by intermittent maintenance.
Withdrawal effects: No formal withdrawal syndrome has been documented. Pigmentation fades gradually over weeks to months as pigmented keratinocytes turn over. Sexual function effects resolve within hours to days.
Tapering: No tapering protocol is required; MT-II can be discontinued abruptly. The short circulating half-life means systemic effects dissipate rapidly, though skin pigmentation persists until normal keratinocyte turnover.
Cycling: No evidence-based cycling protocols exist. Because cumulative melanocyte stimulation is the principal long-term concern, minimizing total exposure is prudent; shorter courses with longer intervals between courses are theoretically preferable but have not been studied.

Sourcing and Quality

Regulatory status: MT-II is not approved as a pharmaceutical by the FDA (US), EMA (European Medicines Agency, the EU regulator), MHRA (UK), or TGA (Australia). All currently marketed MT-II products are obtained through unregulated channels or off-label compounding.
Product quality: Analytical studies of online MT-II products have repeatedly shown variable peptide content, purity, and composition, including contamination and incorrect actives. Forensic identification of black-market melanotan products is an active field of analytical chemistry (e.g., mass-spectrometry methods published by regulatory toxicology groups), underscoring the ongoing quality-assurance gap.
Third-party testing: No established consumer-facing third-party testing program (NSF, USP, ConsumerLab) covers MT-II. If MT-II is obtained through a licensed compounding pharmacy for off-label use, a certificate of analysis showing identity and purity should be requested.
Reputable sources: Licensed compounding pharmacies operating under current Good Manufacturing Practice (cGMP) standards are the only sources with meaningful quality oversight. Peptide vendors marketed as “research chemicals” or “not for human consumption” online are not quality-assured even when they claim third-party testing.
Reconstitution and storage: MT-II is typically supplied as a lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water before subcutaneous injection. Reconstituted vials should be refrigerated and used within 4–6 weeks; freezing and non-sterile diluents compromise peptide integrity.

Practical Considerations

Time to effect: Pro-erectile effects typically occur 1–2 hours after a subcutaneous dose. Appetite suppression is usually immediate but may attenuate with repeated dosing. Visible tanning typically appears within 5–10 doses (1–2 weeks at alternate-day dosing) and darkens further with continued dosing.
Common pitfalls: Purchasing from unregulated online vendors with no identity or purity testing; using supratherapeutic doses to accelerate tanning, which disproportionately increases the risk of severe nausea, cardiovascular events, and rhabdomyolysis; combining MT-II with sunbed use (the most consistent high-risk pattern in the case-report literature); assuming MT-II is safe because it produces a “natural-looking” tan (the tan is cosmetically similar to UV-induced pigmentation but is driven by pharmacological melanocyte stimulation); sharing needles or reconstitution water; and ignoring new or changing moles rather than obtaining prompt dermatologic evaluation.
Regulatory status: MT-II is not approved for any indication. Sale and purchase may violate pharmaceutical regulations depending on jurisdiction; in the UK the MHRA has classified it as an unlicensed medicine, in Australia the TGA has issued explicit warnings against its use, and the FDA has issued import alerts against MT-II products.
Cost and accessibility: Unregulated MT-II is widely available online at roughly 20–50 USD per vial. This price reflects the absence of quality oversight; the true cost of responsible use includes baseline and periodic dermatology assessments, cardiovascular monitoring, and renal laboratory testing.

Interaction with Foundational Habits

Sleep: MT-II’s effect on sleep is direct but typically modest. The Phase I study documented Grade II somnolence and fatigue at 0.03 mg/kg, and a characteristic yawning-stretching complex is commonly reported. Evening dosing generally allows peak somnolence to occur at rest; injections taken in the morning can blunt daytime alertness. There is no evidence that MT-II materially improves sleep architecture, and no polysomnographic studies exist.
Nutrition: The interaction with nutrition is direct and potentiating with restrictive diets. MC4R-mediated hypothalamic appetite suppression combined with post-dose nausea can meaningfully reduce caloric and protein intake, particularly in users already following low-calorie or physique-focused diets in the fitness subculture where MT-II is prevalent. Practical consideration: users tend to eat less on dose days; a protein-forward meal 2–3 hours before injection, and attention to daily protein and micronutrient adequacy, reduces the risk of inadequate intake.
Exercise: The interaction with exercise is direct and primarily blunting at the intensity end. MT-II’s cardiovascular activation (elevated heart rate and blood pressure) and the documented rhabdomyolysis case at supratherapeutic dosing raise concerns about combining high-intensity exercise with recent injection. Practical consideration: avoid vigorous resistance training or prolonged high-heart-rate aerobic work for at least 4–6 hours after a dose; moderate-intensity movement appears well tolerated.
Stress management: The interaction with stress is indirect and potentiating in the short term. MC4R activation recruits the sympathetic nervous system and likely interfaces with the hypothalamic-pituitary-adrenal axis, representing a form of physiological stress activation. Practical consideration: breath-based down-regulation (extended-exhale breathing) and avoidance of additional sympathomimetic inputs (high-dose caffeine, yohimbine, intense stimulant training) on dose days can attenuate sympathetic load.

Monitoring Protocol & Defining Success

A structured monitoring approach is appropriate because MT-II’s safety signals concentrate in skin, cardiovascular, and renal domains, and because users most often self-administer without medical oversight.

Baseline testing: Establish a pre-use assessment covering the main safety domains:

Full-body skin examination with dermoscopic imaging (mole mapping) by a dermatologist.
Seated blood pressure and resting heart rate (averaged across at least two separate measurement sessions).
Complete blood count (CBC, a panel assessing red and white cells and platelets) and comprehensive metabolic panel (CMP, a panel assessing electrolytes, glucose, kidney function including BUN and creatinine, and liver function).
Creatine phosphokinase (CPK, an enzyme released from damaged muscle that rises with muscle injury).
Lipid panel (baseline cardiometabolic reference).

Ongoing monitoring cadence: Measure blood pressure and heart rate before and 1–2 hours after the first several injections, then weekly during active dosing. Repeat serum creatinine at 2 weeks, and monthly thereafter during use. Repeat the full-body skin examination every 3–6 months during and after use. Reassess lipid panel every 6–12 months if use is ongoing.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Blood pressure	<120/80 mmHg	Tracks cardiovascular effect of MC4R activation	Conventional reference: <140/90 mmHg. Measure before and 1–2 hours after first several doses, then weekly.
Resting heart rate	50–70 bpm	Tracks sympathoexcitatory effect	Conventional reference: 60–100 bpm. Measure before and after first several doses, then weekly.
Serum creatinine	0.7–1.1 mg/dL	Screens for renal injury	Conventional reference: 0.6–1.2 mg/dL. Measure at baseline, 2 weeks, monthly thereafter.
BUN	8–18 mg/dL	Adjunct marker of renal function and hydration	Conventional reference: 7–20 mg/dL. Measure with creatinine.
CPK	<150 IU/L	Screens for rhabdomyolysis	Conventional reference: 22–198 IU/L (males), 26–140 IU/L (females). Recheck urgently if severe muscle pain or dark urine appears.
Dermoscopic skin examination	No new or changing nevi	Detects melanocytic change early	Full-body dermoscopic imaging at baseline; repeat every 3–6 months.

Qualitative markers:

Appearance of any new pigmented lesion or change in an existing nevus (size, shape, color, or border).
Severity and frequency of nausea.
Subjective palpitations or chest discomfort.
Erectile function changes and any prolonged or unwanted erections.
Appetite, caloric intake, and perceived nutritional adequacy.
Energy, fatigue, and daytime somnolence.
Injection-site redness, swelling, or pain.

Emerging Research

Several research directions may refine the current understanding of MT-II and related melanocortin pharmacology, cutting both ways:

Vitiligo repigmentation: A Phase II clinical trial, NCT07437560, began recruiting in 2026 to evaluate MT-II as an adjunct to narrowband UV-B phototherapy for repigmentation in stable nonsegmental vitiligo, with a planned enrollment of 60 participants. This is the first registered trial of MT-II under controlled dermatology supervision in the current era and could generate the first modern safety and efficacy data.
Selective melanocortin receptor agonists: Tomassi et al. (2022) used chemical linkage of peptides onto scaffolds (CLIPS) to develop MT-II analogues with improved selectivity for individual melanocortin receptor subtypes. If subtype-selective agents advance clinically, they could isolate pigmentation, sexual, or anti-inflammatory effects while removing off-target cardiovascular and appetite effects.
Behavioral and cognitive signals: Inozemtseva et al. (2024) reported antidepressant-like and antistress effects of MT-II in a rat chronic-unpredictable-stress model, and Wekwejt et al. (2023) reported that MT-II reversed memory impairment induced by a short-term high-fat diet in mice. These preclinical findings open possibilities for cognitive and mood-related applications but are not actionable for humans without controlled clinical data.
Central appetite circuitry: Eliason et al. (2022) showed that microinjection of MT-II into the nucleus accumbens suppressed both appetitive and consummatory food-seeking in a preclinical model, adding nucleus-accumbens circuitry to the known hypothalamic sites of MT-II’s anorexigenic action. This strengthens the mechanistic case for melanocortin-based appetite pharmacology but does not differentiate MT-II from already-approved selective MC4R agonists.
Dermatologic and public-health surveillance: Continued case reports (e.g., Yassin Alsabbagh et al., 2025) and forensic-identification work are likely to expand the catalogue of adverse events associated with unregulated melanotan use, potentially strengthening the case that MT-II’s melanocyte-stimulating activity contributes causally to melanomagenesis in heavily exposed users.

Conclusion

Melanotan II occupies a distinctive and cautionary position among the interventions that health- and longevity-oriented readers encounter. It is an unapproved synthetic peptide with demonstrated biological activity, but its controlled human evidence base is limited to a handful of small early-stage clinical studies in skin tanning and erectile dysfunction, supplemented by an accumulating case-report literature describing serious adverse events including new and changing moles, melanoma, cardiovascular activation, severe muscle breakdown, kidney injury, and prolonged painful erection.

The central pharmacological problem is that the same non-selective melanocortin receptor activation that produces tanning also drives cardiovascular stress, appetite disruption, and widespread melanocyte stimulation. That non-selectivity is what prompted pharmaceutical sponsors to abandon MT-II in favor of more targeted derivatives, two of which have since reached approval. For the target audience, the risk-benefit picture is further complicated by the typical real-world context of use, which combines self-injection, unregulated sourcing of variable-quality product, and frequent concurrent sunbed exposure.

The quality of the evidence base is low overall. The controlled human literature is small, short, and narrow; the case-report literature points toward serious harms but cannot establish causation; and there is no long-term safety follow-up in either direction. Where evidence is available it is most supportive for tanning and erectile function and most concerning for melanocytic and cardiovascular events. For a reader weighing MT-II in a health and longevity context, the principal signal in the current evidence is uncertainty paired with specific and biologically plausible harms, rather than a well-characterized net benefit.

Top - Benefits - Risks - Protocol

Melanotan II for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Skin Pigmentation (Tanning)

Erectile Function Enhancement

Low 🟩

Appetite Suppression

Speculative 🟨

Photoprotection & Skin Cancer Risk Reduction

Anti-Inflammatory & Cardiometabolic Effects

Female Sexual Function

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea

Melanocytic Changes (New & Altered Moles)

Medium 🟥 🟥

Melanoma Risk ⚠️ Conflicted

Cardiovascular Effects (Tachycardia & Blood Pressure Changes)

Facial Flushing

Low 🟥

Rhabdomyolysis & Renal Injury

Priapism

Somnolence, Fatigue & Yawning-Stretching Complex

Speculative 🟨

Endocrine & Metabolic Disruption

Infection Risk from Unregulated Injection Practices

Unknown Long-Term Effects

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion